Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven G Reed

Showing results (231-240 of 263) with videos related to

Pageof 27
Sort By:
Microorganisms|November 27, 2021
Protective Efficacy in a Hamster Model of a Multivalent Vaccine for Human Visceral Leishmaniasis (MuLeVaClin) Consisting of the KMP11, LEISH-F3+, and LJL143 Antigens in Virosomes, Plus GLA-SE AdjuvantLaura Fernández, Jose Carlos Solana, Carmen Sánchez, et al.
Science Translational Medicine|June 5, 2015
A sand fly salivary protein vaccine shows efficacy against vector-transmitted cutaneous leishmaniasis in nonhuman primatesFabiano Oliveira, Edgar Rowton, Hamide Aslan, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 4, 2009
Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeysSteven G Reed, Rhea N Coler, Wilfried Dalemans, et al.
Plos Neglected Tropical Diseases|January 28, 2016
The Severity of Visceral Leishmaniasis Correlates with Elevated Levels of Serum IL-6, IL-27 and sCD14Priscila L Dos Santos, Fabrícia A de Oliveira, Micheli Luize B Santos, et al.
Clinical and Vaccine Immunology : CVI|September 28, 2007
Use of protein antigens for early serological diagnosis of leprosyMalcolm S Duthie, Wakako Goto, Greg C Ireton, et al.
Plos Neglected Tropical Diseases|March 30, 2017
sCD163 levels as a biomarker of disease severity in leprosy and visceral leishmaniasisRicardo Luís Louzada Silva, Marcio B Santos, Priscila L S Almeida, et al.
Clinical & Translational Immunology|July 16, 2015
From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SERhea N Coler, Malcolm S Duthie, Kimberly A Hofmeyer, et al.
Plos One|March 15, 2014
DNA and protein co-immunization improves the magnitude and longevity of humoral immune responses in macaquesRashmi Jalah, Viraj Kulkarni, Vainav Patel, et al.
Scientific Reports|April 22, 2017
A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza VaccinesNeal Van Hoeven, Christopher B Fox, Brian Granger, et al.
Infection and Immunity|November 30, 2016
The Plasmodium falciparum Cell-Traversal Protein for Ookinetes and Sporozoites as a Candidate for Preerythrocytic and Transmission-Blocking VaccinesDiego A Espinosa, Joel Vega-Rodriguez, Yevel Flores-Garcia, et al.
Pageof 27

Showing results (231-240 of 263) with videos related to

Sort By:
Pageof 27
Microorganisms|November 27, 2021
Protective Efficacy in a Hamster Model of a Multivalent Vaccine for Human Visceral Leishmaniasis (MuLeVaClin) Consisting of the KMP11, LEISH-F3+, and LJL143 Antigens in Virosomes, Plus GLA-SE AdjuvantLaura Fernández, Jose Carlos Solana, Carmen Sánchez, et al.
Science Translational Medicine|June 5, 2015
A sand fly salivary protein vaccine shows efficacy against vector-transmitted cutaneous leishmaniasis in nonhuman primatesFabiano Oliveira, Edgar Rowton, Hamide Aslan, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 4, 2009
Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeysSteven G Reed, Rhea N Coler, Wilfried Dalemans, et al.
Plos Neglected Tropical Diseases|January 28, 2016
The Severity of Visceral Leishmaniasis Correlates with Elevated Levels of Serum IL-6, IL-27 and sCD14Priscila L Dos Santos, Fabrícia A de Oliveira, Micheli Luize B Santos, et al.
Clinical and Vaccine Immunology : CVI|September 28, 2007
Use of protein antigens for early serological diagnosis of leprosyMalcolm S Duthie, Wakako Goto, Greg C Ireton, et al.
Plos Neglected Tropical Diseases|March 30, 2017
sCD163 levels as a biomarker of disease severity in leprosy and visceral leishmaniasisRicardo Luís Louzada Silva, Marcio B Santos, Priscila L S Almeida, et al.
Clinical & Translational Immunology|July 16, 2015
From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SERhea N Coler, Malcolm S Duthie, Kimberly A Hofmeyer, et al.
Plos One|March 15, 2014
DNA and protein co-immunization improves the magnitude and longevity of humoral immune responses in macaquesRashmi Jalah, Viraj Kulkarni, Vainav Patel, et al.
Scientific Reports|April 22, 2017
A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza VaccinesNeal Van Hoeven, Christopher B Fox, Brian Granger, et al.
Infection and Immunity|November 30, 2016
The Plasmodium falciparum Cell-Traversal Protein for Ookinetes and Sporozoites as a Candidate for Preerythrocytic and Transmission-Blocking VaccinesDiego A Espinosa, Joel Vega-Rodriguez, Yevel Flores-Garcia, et al.
Pageof 27